CN108982199A - A kind of excrement dilution - Google Patents
A kind of excrement dilution Download PDFInfo
- Publication number
- CN108982199A CN108982199A CN201810917370.XA CN201810917370A CN108982199A CN 108982199 A CN108982199 A CN 108982199A CN 201810917370 A CN201810917370 A CN 201810917370A CN 108982199 A CN108982199 A CN 108982199A
- Authority
- CN
- China
- Prior art keywords
- sodium
- dilution
- excrement
- ethylene diamine
- diamine tetraacetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
- G01N2001/386—Other diluting or mixing processes
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses a kind of concrete component of excrement dilution and mass fraction proportion are as follows: buffer 1.1%-20%, ion concentration regulator 0.01%-0.6%, anti-coagulants 0.01%-0.1%, bacteriostatic agent 0.01%-0.02%, surplus is deionized water；By be added buffer, anti-coagulants and bacteriostatic agent can raising dilution system effectively stability, prevent germ contamination dilution；Meanwhile, it is capable to preferably maintain the form of red blood cell in excrement dilution.
Description
Technical field
The present invention relates to dilution technical fields, more particularly to a kind of excrement dilution.
Background technique
The excrement of people is mainly by unabsorbed food after indigested food, digestion and digestive system secretion, alimentary canal
The composition such as mucous membrane cast and microorganism, helminth, to the excrement of people detect available tester's digestive system function,
Case variation and the information such as microorganism and parasitic infection.When carrying out detection chemical examination to excrement, it usually needs use loose and watery stool
Liquid is released to be diluted excrement.
Existing excrement dilution is mostly tap water, deionized water and physiological saline, and tap water and deionized water cannot
Visible component form in excrement is protected, there is changing at division aspect for diagnostic significance will affect examining for stool for routine
The judgement of disconnected result；In addition, using tap water and deionized water as dilution, when being used for immunochromatographic method occult blood test
Positive rate is lower.Physiological saline is generally used for manual inspection, and physiological saline does not do antibacterial processing, if mating copra analysis
Work station uses, cooperating microorganisms in pipeline, and long-time service may not be suitable for instrument because generating Crystallization Plugging pipeline.
Summary of the invention
To make up for the shortcomings of the above existing technologies, the present invention proposes a kind of excrement dilution.
Technical problem of the invention is resolved by technical solution below:
Concrete component and the mass fraction proportion of a kind of excrement dilution, the excrement dilution are as follows: buffer
1.1%-20%, ion concentration regulator 0.01%-0.6%, anti-coagulants 0.01%-0.1%, bacteriostatic agent 0.01%-0.02%,
Surplus is deionized water.
In certain preferred embodiments, the buffer is the mixture of sodium tetraborate and boric acid；The ion concentration
Regulator is sodium chloride；The anti-coagulants is disodium ethylene diamine tetraacetate；The bacteriostatic agent is sodium benzoate；The excrement dilution
The mass fraction proportion of each component is as follows in liquid: sodium tetraborate 0.1%-0.5%, boric acid 1.0%-2.0%, sodium chloride 0.4%-
0.6%, disodium ethylene diamine tetraacetate 0.01%-0.1%, sodium benzoate 0.01%-0.02%, surplus are deionized water.
In certain preferred embodiments, the buffer is the mixture of sodium tetraborate and boric acid；The ion concentration
Regulator is sodium chloride；The anti-coagulants is disodium ethylene diamine tetraacetate；The bacteriostatic agent is sodium benzoate；The excrement dilution
The mass fraction proportion of each component is as follows in liquid: sodium tetraborate 0.15%, boric acid 1.0%, sodium chloride 0.4%, ethylenediamine tetrem
Acid disodium 0.05%, sodium benzoate 0.01%, surplus are deionized water.
In certain preferred embodiments, the buffer is the mixture of sodium tetraborate and boric acid；The ion concentration
Regulator is sodium chloride；The anti-coagulants is disodium ethylene diamine tetraacetate；The bacteriostatic agent is sodium benzoate；The excrement dilution
The mass fraction proportion of each component is as follows in liquid: sodium tetraborate 0.1%, boric acid 1.0%, sodium chloride 0.5%, ethylenediamine tetra-acetic acid
Disodium 0.05%, sodium benzoate 0.02%, surplus are deionized water.
In certain preferred embodiments, the buffer is the mixture of sodium tetraborate and boric acid；The ion concentration
Regulator is sodium chloride；The anti-coagulants is disodium ethylene diamine tetraacetate；The bacteriostatic agent is sodium benzoate；The excrement dilution
The mass fraction proportion of each component is as follows in liquid: sodium tetraborate 0.15%, boric acid 1.0%, sodium chloride 0.6%, ethylenediamine tetrem
Acid disodium 0.05%, sodium benzoate 0.02%, surplus are deionized water.
In certain preferred embodiments, the buffer is the mixed of disodium hydrogen phosphate and sodium dihydrogen phosphate dihydrate
Close object；The ion concentration regulator is potassium dihydrogen phosphate；The anti-coagulants is disodium ethylene diamine tetraacetate；The bacteriostatic agent is
Sodium benzoate；The mass fraction proportion of each component is as follows in the excrement dilution: disodium hydrogen phosphate 2%-6%, and two
Water sodium dihydrogen phosphate 0.1%-0.8%, potassium dihydrogen phosphate 0.01%-0.085%, disodium ethylene diamine tetraacetate 0.01%-
0.1%, sodium benzoate 0.01%-0.02%, surplus is deionized water.
In certain preferred embodiments, the buffer is the mixture of trishydroxymethylaminomethane and concentrated hydrochloric acid；Institute
Stating ion concentration regulator is sodium chloride；The anti-coagulants is disodium ethylene diamine tetraacetate；The bacteriostatic agent is sodium benzoate；Institute
The mass fraction proportion for stating each component in excrement dilution is as follows: trishydroxymethylaminomethane 5%-15%, concentrated hydrochloric acid 1%-
5%, sodium chloride 0.4%-0.6%, disodium ethylene diamine tetraacetate 0.01%-0.1%, sodium benzoate 0.01%-0.02%, surplus
For deionized water.
The beneficial effect of the present invention compared with the prior art includes:
Concrete component and the mass fraction proportion of excrement dilution in the present invention are as follows: buffer 1.1%-20%, from
Sub- concentration regulator 0.01%-0.6%, anti-coagulants 0.01%-0.1%, bacteriostatic agent 0.01%-0.02%, surplus are deionization
Water；By be added buffer, anti-coagulants and bacteriostatic agent can raising dilution system effectively stability, prevent bacterium dirty
Contaminate dilution；Meanwhile, it is capable to preferably maintain the form of red blood cell in excrement dilution.
Specific embodiment
The following further describes the present invention in combination with preferred embodiments.
Embodiment 1
The mass fraction proportion of each component is as follows in excrement dilution: sodium tetraborate 0.15%, boric acid 1.0%, sodium chloride
0.4%, disodium ethylene diamine tetraacetate 0.05%, sodium benzoate 0.01%, surplus is deionized water.
RBC deformation and rupture rate measurement:
Take excrement dilution 10ml in test tube A, take 0.9% physiological saline 10ml in test tube B.Respectively to test tube A, B
50 μ l red blood cell samples of middle addition mix.It is instilled in 2-3d test tube A, B into cell counting board A, B respectively and mixes sample, used
Biomicroscope carries out total amount to red blood cell in the counting frame of cell counting board and paramophia quantity counts, and counts according to the following formula
RBC deformation rate and rupture rate are calculated, the results are shown in Table 1.
Red cell morphology deformation rate (%)=abnormal erhythrocyte number ÷ Erythrocytes × 100%
Embodiment 2
The mass fraction proportion of each component is as follows in excrement dilution: sodium tetraborate 0.1%, boric acid 1.0%, sodium chloride
0.5%, disodium ethylene diamine tetraacetate 0.05%, sodium benzoate 0.02%, surplus is deionized water.
RBC deformation and rupture rate measurement:
Take excrement dilution 10ml in test tube A, take 0.9% physiological saline 10ml in test tube B.Respectively to test tube A, B
50 μ l red blood cell samples of middle addition mix.It is instilled in 2-3d test tube A, B into cell counting board A, B respectively and mixes sample, used
Biomicroscope carries out total amount to red blood cell in the counting frame of cell counting board and paramophia quantity counts, and counts according to the following formula
RBC deformation rate and rupture rate are calculated, the results are shown in Table 1.
Red cell morphology deformation rate (%)=abnormal erhythrocyte number ÷ Erythrocytes × 100%
Embodiment 3
The mass fraction proportion of each component is as follows in excrement dilution: sodium tetraborate 0.15%, boric acid 1.0%, sodium chloride
0.6%, disodium ethylene diamine tetraacetate 0.05%, sodium benzoate 0.02%, surplus is deionized water.
RBC deformation and rupture rate measurement:
Take excrement dilution 10ml in test tube A, take 0.9% physiological saline 10ml in test tube B.Respectively to test tube A, B
50 μ l red blood cell samples of middle addition mix.It is instilled in 2-3d test tube A, B into cell counting board A, B respectively and mixes sample, used
Biomicroscope carries out total amount to red blood cell in the counting frame of cell counting board and paramophia quantity counts, and counts according to the following formula
RBC deformation rate and rupture rate are calculated, the results are shown in Table 1.
Red cell morphology deformation rate (%)=abnormal erhythrocyte number ÷ Erythrocytes × 100%
Excrement dilution and 09% physiological saline are to RBC deformation and destructive rate in each embodiment of table 1
The above results show: excrement dilution is close to RBC deformation rate with 0.9% physiological saline, all lower, to red
The rupture rate of cell illustrates that excrement dilution maintains red cell morphology to work well close to 0.
The test of shelf-life:
Excrement dilution and 0.9% physiological saline in Example 1 are placed 6 months respectively, observe excrement every other month
Just dilution and 0.9% physiological saline situation, and record.
Experimental result is as follows: excrement dilution increasingly generates floccule without significant change, physiological saline.
It picks and places the excrement dilution after setting 6 months and measures its survey to RBC deformation and destructive rate as the method previously described
Examination.
Experimental result is as follows: the excrement dilution of placement 6 months, substantially without influence, shows that excrement dilutes to red cell morphology
The shelf-life of liquid is longer with respect to 0.9% physiological saline.
The above content is a further detailed description of the present invention in conjunction with specific preferred embodiments, and it cannot be said that
Specific implementation of the invention is only limited to these instructions.For those skilled in the art to which the present invention belongs, it is not taking off
Under the premise of from present inventive concept, several equivalent substitute or obvious modifications can also be made, and performance or use is identical, all answered
When being considered as belonging to protection scope of the present invention.
Claims (7)
1. a kind of excrement dilution, which is characterized in that concrete component and the mass fraction proportion of the excrement dilution are as follows: slow
Electuary 1.1%-20%, ion concentration regulator 0.01%-0.6%, anti-coagulants 0.01%-0.1%, bacteriostatic agent 0.01%-
0.02%, surplus is deionized water.
2. excrement dilution as described in claim 1, which is characterized in that the buffer is the mixing of sodium tetraborate and boric acid
Object；The ion concentration regulator is sodium chloride；The anti-coagulants is disodium ethylene diamine tetraacetate；The bacteriostatic agent is benzoic acid
Sodium；The mass fraction proportion of each component is as follows in the excrement dilution: sodium tetraborate 0.1%-0.5%, boric acid 1.0%-
2.0%, sodium chloride 0.4%-0.6%, disodium ethylene diamine tetraacetate 0.01%-0.1%, sodium benzoate 0.01%-0.02% are remaining
Amount is deionized water.
3. excrement dilution as described in claim 1, which is characterized in that the buffer is the mixing of sodium tetraborate and boric acid
Object；The ion concentration regulator is sodium chloride；The anti-coagulants is disodium ethylene diamine tetraacetate；The bacteriostatic agent is benzoic acid
Sodium；The mass fraction proportion of each component is as follows in the excrement dilution: sodium tetraborate 0.15%, boric acid 1.0%, sodium chloride
0.4%, disodium ethylene diamine tetraacetate 0.05%, sodium benzoate 0.01%, surplus is deionized water.
4. excrement dilution as described in claim 1, which is characterized in that the buffer is the mixing of sodium tetraborate and boric acid
Object；The ion concentration regulator is sodium chloride；The anti-coagulants is disodium ethylene diamine tetraacetate；The bacteriostatic agent is benzoic acid
Sodium；The mass fraction proportion of each component is as follows in the excrement dilution: sodium tetraborate 0.1%, boric acid 1.0%, sodium chloride
0.5%, disodium ethylene diamine tetraacetate 0.05%, sodium benzoate 0.02%, surplus is deionized water.
5. excrement dilution as described in claim 1, which is characterized in that the buffer is the mixing of sodium tetraborate and boric acid
Object；The ion concentration regulator is sodium chloride；The anti-coagulants is disodium ethylene diamine tetraacetate；The bacteriostatic agent is benzoic acid
Sodium；The mass fraction proportion of each component is as follows in the excrement dilution: sodium tetraborate 0.15%, boric acid 1.0%, sodium chloride
0.6%, disodium ethylene diamine tetraacetate 0.05%, sodium benzoate 0.02%, surplus is deionized water.
6. excrement dilution as described in claim 1, which is characterized in that the buffer is disodium hydrogen phosphate and two
The mixture of water sodium dihydrogen phosphate；The ion concentration regulator is potassium dihydrogen phosphate；The anti-coagulants is ethylenediamine tetra-acetic acid
Disodium；The bacteriostatic agent is sodium benzoate；The mass fraction proportion of each component is as follows in the excrement dilution: ten phosphate dihydrates
Disodium hydrogen 2%-6%, sodium dihydrogen phosphate dihydrate 0.1%-0.8%, potassium dihydrogen phosphate 0.01%-0.085%, ethylenediamine tetra-acetic acid
Disodium 0.01%-0.1%, sodium benzoate 0.01%-0.02%, surplus are deionized water.
7. excrement dilution as described in claim 1, which is characterized in that the buffer is trishydroxymethylaminomethane and dense
The mixture of hydrochloric acid；The ion concentration regulator is sodium chloride；The anti-coagulants is disodium ethylene diamine tetraacetate；It is described antibacterial
Agent is sodium benzoate；The mass fraction proportion of each component is as follows in the excrement dilution: trishydroxymethylaminomethane 5%-
15%, concentrated hydrochloric acid 1%-5%, sodium chloride 0.4%-0.6%, disodium ethylene diamine tetraacetate 0.01%-0.1%, sodium benzoate
0.01%-0.02%, surplus are deionized water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810917370.XA CN108982199A (en) | 2018-08-13 | 2018-08-13 | A kind of excrement dilution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810917370.XA CN108982199A (en) | 2018-08-13 | 2018-08-13 | A kind of excrement dilution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108982199A true CN108982199A (en) | 2018-12-11 |
Family
ID=64553296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810917370.XA Pending CN108982199A (en) | 2018-08-13 | 2018-08-13 | A kind of excrement dilution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108982199A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111139236A (en) * | 2019-12-26 | 2020-05-12 | 深圳市南山区慢性病防治院 | Feces sample stabilizing solution and preparation and use methods thereof |
| CN111505272A (en) * | 2020-04-20 | 2020-08-07 | 石家庄洹众生物科技有限公司 | Excrement diluent and application thereof |
| CN112985966A (en) * | 2021-02-08 | 2021-06-18 | 桂林优利特医疗电子有限公司 | Diluent for analyzing urine visible components and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101692073A (en) * | 2009-07-29 | 2010-04-07 | 南开大学 | Method for measuring antibiotic in animal excretion |
| CN106769289A (en) * | 2016-12-02 | 2017-05-31 | 刘鹏飞 | A kind of collocation method of fecal specimens storage liquid and application |
-
2018
- 2018-08-13 CN CN201810917370.XA patent/CN108982199A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101692073A (en) * | 2009-07-29 | 2010-04-07 | 南开大学 | Method for measuring antibiotic in animal excretion |
| CN106769289A (en) * | 2016-12-02 | 2017-05-31 | 刘鹏飞 | A kind of collocation method of fecal specimens storage liquid and application |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111139236A (en) * | 2019-12-26 | 2020-05-12 | 深圳市南山区慢性病防治院 | Feces sample stabilizing solution and preparation and use methods thereof |
| CN111505272A (en) * | 2020-04-20 | 2020-08-07 | 石家庄洹众生物科技有限公司 | Excrement diluent and application thereof |
| CN112985966A (en) * | 2021-02-08 | 2021-06-18 | 桂林优利特医疗电子有限公司 | Diluent for analyzing urine visible components and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108982199A (en) | A kind of excrement dilution | |
| Moncla et al. | Degradation of naturally occurring and engineered antimicrobial peptides by proteases | |
| Yoshino et al. | In vitro cytotoxicity of white MTA, MTA Fillapex® and Portland cement on human periodontal ligament fibroblasts | |
| Yang et al. | Inhibition of iron overload-induced apoptosis and necrosis of bone marrow mesenchymal stem cells by melatonin | |
| Leung et al. | False-negative biopsy urease test in bleeding ulcers caused by the buffering effects of blood | |
| Hiremath et al. | Evaluation of minimal inhibitory concentration of two new materials using tube dilution method: An: in vitro: study | |
| CN101281194B (en) | Blood cell analyzer cleaning fluid | |
| Brodzki et al. | Trueperella pyogenes and Escherichia coli as an etiological factor of endometritis in cows and the susceptibility of these bacteria to selected antibiotics | |
| CN107805656A (en) | A kind of culture medium and detection method for detecting Bifidobacterium | |
| Moncla et al. | Testing of viscous anti-HIV microbicides using Lactobacillus | |
| Weckwerth et al. | Effects of the association of antifungal drugs on the antimicrobial action of endodontic sealers | |
| O'Sullivan et al. | A simplified method for the quantitative bacterial culture of urine | |
| GB2059435A (en) | Selective isolation medium for cholera vibrio | |
| Kangarlou et al. | Assessment of antifungal activity of ProRoot mineral trioxide aggregate and mineral trioxide aggregate-Angelus | |
| CN103911423B (en) | Antibacterial peptide activity detection kit and detection method | |
| Vandenberg et al. | Improvement of routine diagnosis of intestinal parasites with multiple sampling and SAF-fixative in the triple-faeces-test | |
| Marciano et al. | Influence of bismuth oxide concentration on the pH level and biocompatibility of white Portland cement | |
| KOSKENEN et al. | Cytotoxicity of some solutions used for root canal treatment assessed with unman fibroblasts and lymphoblasts | |
| Gallinger et al. | Effect of binding of ionised calcium on the in vitro nucleation of cholesterol and calcium bilirubinate in human gall bladder bile. | |
| CN112741080B (en) | Liquid-based cell preservation treatment liquid and preparation method and application thereof | |
| Alwahaibi et al. | Capability of hematoxylin and eosin stain to demonstrate hemosiderin in bone marrow trephine biopsy | |
| Maçin et al. | Microbiological evaluation of an acute gastroenteritis outbreak | |
| Francis et al. | Diagnosis of lung disease in acquired immune deficiency syndrome: biopsy or cytology and implications for management. | |
| CN112574938A (en) | Sputum treatment fluid for membrane filtration enriched bacteria and application thereof | |
| CN111505272A (en) | Excrement diluent and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181211 |
|
| RJ01 | Rejection of invention patent application after publication |